KING OF PRUSSIA, Pa., Jan. 11, 2022 /PRNewswire/ --
Ø South Korea conglomerate, SK, Inc., and the Center for Breakthrough Medicines announce landmark deal at 40th annual JP Morgan Healthcare Conference
Ø SK's $350MM investment in the Philadelphia-based Center for Breakthrough Medicines transforms the global cell & gene therapy landscape
Ø Blockbuster deal solidifies Philadelphia as "Cellicon Valley;" strengthens Philadelphia as a global hub for cell & gene therapy research, development and manufacturing
Ø Deal sets stage for massive hiring in the Philadelphia region
Ø This historical deal officially closed yesterday and was announced here.
Ø CBM and SK c-suite executives are available for interviews.
Ø For more information and to arrange interviews:
John F. Kouten
O - 609-241-7352
M – 908-227-4714
View original content:
SOURCE Center for Breakthrough Medicines